Good outcome with trimethoprim 10 mg/kg/day-sulfamethoxazole 50 mg/kg/day for Pneumocystis jirovecii pneumonia in HIV infected patients

Scandinavian Journal of Infectious Diseases

Volumn 41, Issue 11-12, 2009, Pages 862-868

  Thomas, Mark G ^a   Rupali, Priscilla ^a   Woodhouse, Andrew ^a   Ellis Pegler, Rod ^a  

^a AUCKLAND CITY HOSPITAL   (New Zealand)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRETROVIRUS AGENT; CLINDAMYCIN; CORTICOSTEROID; COTRIMOXAZOLE; DAPSONE; PENTAMIDINE; PRIMAQUINE; TRIMETHOPRIM;

ADULT; AGED; ARTICLE; CORTICOSTEROID THERAPY; DOSAGE SCHEDULE COMPARISON; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG FATALITY; FEVER; HEADACHE; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HOSPITAL ADMISSION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INCIDENCE; INTENSIVE CARE UNIT; MAJOR CLINICAL STUDY; MORTALITY; NEUTROPENIA; OUTCOME ASSESSMENT; OXYGEN SATURATION; PNEUMOCYSTIS JIROVECI; PNEUMOCYSTIS PNEUMONIA; RASH; RETROSPECTIVE STUDY; TREATMENT DURATION; TREATMENT OUTCOME;

ADULT; AGED; AIDS-RELATED OPPORTUNISTIC INFECTIONS; ANTI-INFECTIVE AGENTS; FEMALE; HIV INFECTIONS; HUMANS; LOGISTIC MODELS; MALE; MIDDLE AGED; PNEUMOCYSTIS JIROVECII; PNEUMONIA, PNEUMOCYSTIS; RETROSPECTIVE STUDIES; SULFAMETHOXAZOLE; TREATMENT OUTCOME; TRIMETHOPRIM-SULFAMETHOXAZOLE COMBINATION;

EID: 70450175591     PISSN: 00365548     EISSN: 16511980     Source Type: Journal    
DOI: 10.3109/00365540903214256     Document Type: Article

References (25)

1. Centers for Disease Control and Prevention. Treating opportunistic infections among HIV-infected adults and adolescents: recommendations from the CDC, the National Institutes of Health, and the HIV Medicine Association/ Infectious Diseases Society of America. MMWR Recomm Rep 2004;53(RR-15):1-112.
2. Hughes WT,McNabb PC, Makres TD, Feldman S. Efficacy of trimethoprim and sulfamethoxazole in the prevention and treatment of Pneumocystis carinii pneumonitis. Antimicrob Agents Chemother 1974;/5:/289-93.
3. Hughes WT, Feldman S, Sanyal SK. Treatment of Pneumocystis carinii pneumonitis with trimethoprim- sulfamethoxazole. Can Med Assoc J 1975;/112:/47S-50S.
4. Hughes WT. Trimethoprim- sulfamethoxazole therapy for Pneumocystis carinii pneumonitis in children. Rev Infect Dis 1982;/4:/602-7.
5. Vohringer HF, Arasteh K. Pharmacokinetic optimisation in the treatment of Pneumocystis carinii pneumonia. Clin Pharmacokinet 1993;/24:/388-412.
6. Young LS. Trimethoprim- sulfamethoxazole in the treatment of adults with pneumonia due to Pneumocystis carinii. Rev Infect Dis 1982;/4:/608-13.
7. Sattler FR, Cowan R, Nielsen DM, Ruskin J. Trimethoprim- sulfamethoxazole compared with pentamidine for treatment of Pneumocystis carinii pneumonia in the acquired immunodeficiency syndrome. Ann Intern Med 1988;/109:/280-7.
8. Ingram RJ, Davis R, Ellis-Pegler RB. Experience with Pneumocystis carinii pneumonia in patients with AIDS. N Z Med J 1989;/102:/496-8.
9. Safrin S, Finkelstein DM, Feinberg J, Frame P, Simpson G, Wu A, et al. Comparison of three regimens for treatment of mild to moderate Pneumocystis carinii pneumonia in patients with AIDS. Ann Intern Med 1996;/124:/792-802.
10. Sattler FR, Frame P, Davis R, Nichols L, Shelton B, Akil B, et al. Trimetrexate with leucovorin versus trimethoprim- sulfamethoxazole for moderate to severe episodes of Pneumocystis carinii pneumonia in patients with AIDS: a prospective, controlled multicenter investigation of the AIDS Clinical Trials Group protocol 029/031. J Infect Dis 1994;/170:/165-72.
11. Benfield TL, Helweg-Larsen J, Bang D, Junge J, Lundgren JD. Prognostic markers of short-term mortality in AIDSassociated Pneumocystis carinii pneumonia. Chest 2001;/ 119:/844-51.
12. Dworkin MS, Hanson DL, Navin TR; and the Adult and Adolescent Spectrum HIV Disease Project. Survival of patients with AIDS, after diagnosis of Pneumocystis carinii pneumonia, in the United States. J Infect Dis 2001;183: 1409-1412
13. Walzer PD, Evans HE, Copas AJ, Edwards SG, Grant AD, Miller RF. Early predictors of mortality from Pneumocystis jirovecii pneumonia in HIV-infected patients: 1985-2006. Clin Infect Dis 2008;/46:/625-33.
14. Morris A, Wachter RM, Luce J, Turner J, Huang L. Improved survival with highly active antiretroviral therapy in HIV-infected patients with severe Pneumocystis carinii pneumonia. AIDS 2003;/17:/73-80.
15. Dickson SJ, Batson S, Copas AJ, Edwards SG, Singer M, Miller RF. Survival of HIV-infected patients in the intensive care unit in the era of highly active antiretroviral therapy. Thorax 2007;/62:/964-8.
16. Curtis JR, Yarnold PR, Schwartz DN, Weinstein RA, Bennett CL. Improvements in outcomes of acute respiratory failure for patients with human immunodeficiency virusrelated Pneumocystis carinii pneumonia. Am J Respir Crit Care Med 2000;/162:/393-8.
17. Lee BL, Medina I, Benowitz NL, Jacob P,Wofsy CB, Mills J. Dapsone, trimethoprim, and sulfamethoxazole plasma levels during treatment of Pneumocystis pneumonia in patients with the acquired immunodeficiency syndrome (AIDS). Ann Intern Med 1989;/110:/606-11.
18. Joos B, Blaser J, Opravil M, Chave JP, Luthy R. Monitoring of co-trimoxazole concentrations in serum during treatment of Pneumocystis carinii pneumonia. Antimicrob Agents Chemother 1995;/39:/2661-6.
19. Mashford L, Lucas CR, Stewart K, Bowden FJ. Serum levels of trimethoprim and sulfamethoxazole following a lower dose of cotrimoxazole in the treatment of Pneumocystis carinii pneumonia [Abstract]. 7th International Conference on AIDS. Florence 1991; WB2183.
20. Data from the European Committee on Antimicrobial Susceptibility Testing (EUCAST); 2008-9-23. Available at: http://www.eucast.org (accessed on November 10, 2008).
21. van der Ven AJ, Schoondermark-van de Ven EM, Camps W, Melchers WJ, Koopmans PP, van der Meer JW, et al. Antitoxoplasma effect of pyrimethamine, trimethoprim and sulphonamides alone and in combination: implications for therapy. J Antimicrob Chemother 1996;/38:/75-80.
22. Daramola OO, Alonso PL, O'Dempsey TJD, Twumasi P, McArdle TF, Greenwood BM. Sensitivity of Plasmodium falciparum in The Gambia to co-trimoxazole. Trans R Soc Trop Med Hyg 1991;/84:/345-8.
23. Jordan GW, Krajden SF, Hoeprich PD, Wong GA, Pierce TH, Rausch DC. Trimethoprim- sulfamethoxazole in chronic bronchitis. Can Med Assoc J 1975;/112:/91S-95S.
24. Morel C, Bergogne-Berezin E, Benard Y. Diffusion intrabronchique de l'association sulfamethoxazole-trimethoprime. Med Mal Infect 1979;/9:/217-22.
25. Hughes W, Leoung G, Kramer F, Bozzette SA, Safrin S, Frame P, et al. Comparison of atovaquone (566C80) with trimethoprim- sulfamethoxazole to treat Pneumocystis carinii pneumonia in patients with AIDS. N Engl J Med 1993;/ 328:/1521-7.